Zoldonrasib (RMC-9805) shows promising results in KRAS G12D-mutant NSCLC with 52% ORR, 11.1 months median PFS, and a favorable safety profile in the Phase 1 study Ask about FDA oncology approvals, clinical trials, and treatment guidelines. Launch Oncology AI Chat...
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON)...
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) - Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON)...
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON)...
REDWOOD CITY, Calif., April 19, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) clinical data for zoldonrasib, an oral RAS(ON)...
Revolution Medicines Presents Updated Phase 1 Clinical Data For Zoldonrasib In Patients With Previously Treated KRAS G12D Non-Small Cell Lung Cancer Published on 04/19/2026 at 02:00 pm EDT S&P Capital IQ Share REVOLUTION MEDICINES, INC. -0.43% Revolution Medicines, Inc. announced...
Ahmet Dirican: KRAS G12D Was Considered Untouchable For Years, But Not Anymore Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared a post on X:. “For years, KRAS G12D was considered untouchable. Not anymore. In this phase...
A phase I, first-in-human study involving patients with previously treated locally advanced unresectable or metastatic solid tumours harbouring KRAS p.G12D variants according to local or central testing, evaluated the safety profile and clinical activity of setidegrasib, a first-in-class, selective KRAS...
